TY - JOUR
T1 - Drugging the efferocytosis process
T2 - concepts and opportunities
AU - Mehrotra, Parul
AU - Ravichandran, Kodi S.
N1 - Funding Information:
The authors thank the members of the Ravichandran laboratory for numerous discussions. This work was supported by Fonds Wetenschappelijk Onderzoek (FWO) Odysseus grant G0F5716N, EOS DECODE 30837538, Special Research Fund UGent (iBOF BOF20/IBF/037), European Research Council (ERC) (grant agreement no. 835243) and grants from the National Heart, Lung, and Blood Institute (NHLBI) (P01HL120840), National Institute of Allergy and Infectious Diseases (NIAID) (R01AI159551) and National Institute of General Medical Sciences (NIGMS) (R35GM122542). P.M. is supported by a FWO Postdoctoral Fellowship (1227220N).
Publisher Copyright:
© 2022, Springer Nature Limited.
PY - 2022
Y1 - 2022
N2 - The daily removal of billions of apoptotic cells in the human body via the process of efferocytosis is essential for homeostasis. To allow for this continuous efferocytosis, rapid phenotypic changes occur in the phagocytes enabling them to engulf and digest the apoptotic cargo. In addition, efferocytosis is actively anti-inflammatory and promotes resolution. Owing to its ubiquitous nature and the sheer volume of cell turnover, efferocytosis is a point of vulnerability. Aberrations in efferocytosis are associated with numerous inflammatory pathologies, including atherosclerosis, cancer and infections. The recent exciting discoveries defining the molecular machinery involved in efferocytosis have opened many avenues for therapeutic intervention, with several agents now in clinical trials.
AB - The daily removal of billions of apoptotic cells in the human body via the process of efferocytosis is essential for homeostasis. To allow for this continuous efferocytosis, rapid phenotypic changes occur in the phagocytes enabling them to engulf and digest the apoptotic cargo. In addition, efferocytosis is actively anti-inflammatory and promotes resolution. Owing to its ubiquitous nature and the sheer volume of cell turnover, efferocytosis is a point of vulnerability. Aberrations in efferocytosis are associated with numerous inflammatory pathologies, including atherosclerosis, cancer and infections. The recent exciting discoveries defining the molecular machinery involved in efferocytosis have opened many avenues for therapeutic intervention, with several agents now in clinical trials.
UR - http://www.scopus.com/inward/record.url?scp=85131313037&partnerID=8YFLogxK
U2 - 10.1038/s41573-022-00470-y
DO - 10.1038/s41573-022-00470-y
M3 - Review article
C2 - 35650427
AN - SCOPUS:85131313037
SN - 1474-1776
JO - Nature Reviews Drug Discovery
JF - Nature Reviews Drug Discovery
ER -